Condition

Stage IIIA Breast Cancer AJCC v7

ClinicalTrials.gov condition label

Clinical trials35
Recruiting0
Common interventions25
Lead sponsors shown10

Clinical trials

35 shown
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and SurgeryNCT04197687 · 2020-02-20
UNKNOWN
Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant ChemotherapyNCT03872388 · 2019-09-23
TERMINATED
Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy AdherenceNCT04054557 · 2019-07-31
COMPLETED
SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast CancerNCT03411070 · 2019-04-07
COMPLETED
Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer SurvivorsNCT03407716 · 2019-03-01
COMPLETED
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast SurgeryNCT03317405 · 2018-10-31
ACTIVE_NOT_RECRUITING
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and NeratinibNCT03094052 · 2018-10-09
COMPLETED
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic InstabilityNCT03428802 · 2018-03-08
ACTIVE_NOT_RECRUITING
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast CancerNCT03101748 · 2018-02-19
TERMINATED
Hypofractionated Radiation Therapy in Preventing Recurrence in Patients With Breast Cancer After SurgeryNCT03324802 · 2018-02-07
COMPLETED
Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine TherapyNCT03281902 · 2017-11-13
ACTIVE_NOT_RECRUITING
Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast CancerNCT03106415 · 2017-09-27
COMPLETED
Kindness Interventions in Enhancing Well-Being in Breast Cancer SurvivorsNCT03319342 · 2017-07-11
COMPLETED
Magseed Magnetic Marker in Locating Axillary Lymph Nodes in Patients With Breast Cancer Undergoing SurgeryNCT03038152 · 2017-04-11
COMPLETED
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast CancerNCT03012100 · 2017-03-31
ACTIVE_NOT_RECRUITING
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast CancerNCT02912312 · 2017-02-23
ACTIVE_NOT_RECRUITING
Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBCNCT02593175 · 2016-11-03
COMPLETED
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast CancerNCT02689427 · 2016-09-22
COMPLETED
Breast Cancer WEight Loss Study (BWEL Study)NCT02750826 · 2016-09-16
ACTIVE_NOT_RECRUITING
Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer TreatmentNCT02754752 · 2016-09-13
ACTIVE_NOT_RECRUITING
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsNCT02498613 · 2016-08-31
ACTIVE_NOT_RECRUITING
Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast CancerNCT02474173 · 2016-01-15
TERMINATED
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot InitiativeNCT02276443 · 2015-11-09
ACTIVE_NOT_RECRUITING
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast CancerNCT02311933 · 2015-05-28
ACTIVE_NOT_RECRUITING
Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive PatientsNCT02152943 · 2014-07-17
COMPLETED
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast CancerNCT02003209 · 2014-02-18
COMPLETED
The Role of Lifestyle Factors in Breast Cancer-Related OutcomesNCT02079662 · 2013-06-13
ACTIVE_NOT_RECRUITING
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign DiseaseNCT01552434 · 2012-10-16
TERMINATED
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionNCT01638533 · 2012-08-03
COMPLETED
Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast CancerNCT01463072 · 2012-06-19
ACTIVE_NOT_RECRUITING
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast CancerNCT01275677 · 2011-02-08
COMPLETED
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by SurgeryNCT00861705 · 2009-07-21
COMPLETED
Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by SurgeryNCT00770809 · 2009-02-24
COMPLETED
Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast CancerNCT00376688 · 2006-07-11
COMPLETED
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast CancerNCT00005970 · 2000-05-19
COMPLETED

Common interventions

Laboratory Biomarker AnalysisOTHER23PaclitaxelDRUG8Questionnaire AdministrationOTHER8TrastuzumabBIOLOGICAL8Quality-of-Life AssessmentOTHER7CyclophosphamideDRUG5Pharmacological StudyOTHER4CarboplatinDRUG3Doxorubicin HydrochlorideDRUG3PertuzumabBIOLOGICAL3Placebo AdministrationOTHER3Therapeutic Conventional SurgeryPROCEDURE3Aromatase Inhibition TherapyDRUG2Axillary Lymph Node DissectionPROCEDURE2Behavioral InterventionBEHAVIORAL2Best PracticeOTHER2BevacizumabBIOLOGICAL2DocetaxelDRUG2DoxorubicinDRUG2Endoxifen HydrochlorideDRUG2Hypofractionated Radiation TherapyRADIATION2Lymph Node BiopsyPROCEDURE2NeratinibDRUG2PembrolizumabBIOLOGICAL2Radiation TherapyRADIATION2

Trial status mix

COMPLETED18
ACTIVE_NOT_RECRUITING12
TERMINATED4
UNKNOWN1

Phase mix

PHASE216
PHASE17
PHASE36
NA4
EARLY_PHASE12
PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.